Krystal Biotech Stock
Krystal Biotech Stock
There is an upward development for Krystal Biotech compared to yesterday, with an increase of €6.60 (2.910%).
With 25 Buy predictions and not a single Sell prediction Krystal Biotech is an absolute favorite of our community.
As a result the target price of 234 € shows a slightly positive potential of 1.47% compared to the current price of 230.6 € for Krystal Biotech.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Krystal Biotech stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Krystal Biotech in the next few years
Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | 2.910% | -4.156% | -3.191% | 33.720% | 6.365% | 209.530% | - |
| Biocryst Pharmaceuticals | 2.500% | 3.665% | 11.204% | -18.883% | -2.502% | -25.950% | -25.709% |
| Heron Therapeutics Inc. | 13.090% | -10.600% | -27.845% | -44.230% | -19.749% | -58.544% | -93.972% |
| Madrigal Pharmaceuticals inc. | 0.110% | -11.652% | -9.393% | 25.170% | -26.078% | 40.649% | 264.671% |
Comments
Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $220.00 to $323.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for KRYS provided by MarketBeat